Severe asthma drug may boost daily steps, study hopes

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 18 and 75 years at the time of inclusion * Asthma diagnosed for at least one year including a history of 1. FEV1 and/or FVC reversibility of more than 12% and than 200 ml documented in the patient's record 2. OR FEV1 variability of more than 20% between two visits 3. OR positive methacholine test * Severe uncontrolled asthma monitored for at least six months in the investigation center with at least two assessments: 1. high-dose of inhaled corticosteroids (ICS \>1,000 μg/day of beclometasone equivalent) in combination with another controller at a stable dosage for at least three months 2. ACQ-5 score \>1.5 and/or more than two severe exacerbations (i.e exacerbation requiring ≥ 3 days of systemic corticosteroids, hospitalization or admission at the emergency department) in the past year 3. Blood eosinohils ≥300/mm3 within the 12 past months 4. Decision to introduce mepolizumab according to regulatory approval 5. Patient agreement to receive Mepolizumab * Body mass index (BMI) within the range \[18.5 - 35\] kg/m2. * Able to give signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol Exclusion Criteria: * Body Mass Index \<18.5 or \>35 kg/m2 * Active smoker or active smoking during the last 6 months or cumulative \> 10 pack-years * All conditions responsible for physical disability (neurological, orthopedic, psychiatric, non-exhaustive list) or other condition limiting exercise in the investigator's opinion * Any chronic respiratory or cardiac pathology which may interfere with the assessment of asthma according to the investigator's opinion * Prior treatment with mepolizumab or benralizumab * Bronchial thermoplasty during the past 12 months * Contraindication to mepolizumab * Non-coverage by the social security insurance * Pregnant, breastfeeding, or lactating women * Patient unable to receive information * Refusal to sign the consent form * Unwillingness or inability to follow the study procedures, in the opinion of the investigator * Person deprived of the liberty Person benefiting from a system of legal protection (guardianship…)